Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al. - Researchers conducted this randomized clinical trials to test the effectiveness of galcanezumab [a humanized monoclonal antibody against calcitonin-gene-related peptide] in patients with episodic migraine and history of preventive treatment failure. Study participants were randomized 2:1:1 to monthly injections of placebo, galcanezumab 120 mg/240 mg during the 6-month double-blind treatment period. Among patients with episodic migraine treated with galcanezumab, there were significantly greater increases in efficacy results for those with ≥ 1 or ≥ 2 previous preventive failures compared to placebo. Similar outcomes were found with greater placebo response in patients with no previous failure.